Overview of Azestan

What is Azestan? Identity, Classification, and Forms

Azestan is a prescription-only medication defined by its active ingredient, Octreotide. This foundational section details the drug's core identity, pharmacological classification, and available delivery formats.

Quick Facts

Property	Description
Active ingredient	Octreotide (synthetic octapeptide)
Forms	Solution for injection, Long-acting suspension (LAR), Delayed-release capsule
Pharmacological class	Somatostatin Analog
General purpose	Hormonal inhibitor and secretagogue suppressant
Origin	Synthetic (derived from natural Somatostatin)

Azestan’s Identity: Octreotide and Its Origin

The core component of Azestan is Octreotide, a substance classified as a synthetic octapeptide. This designation signifies that it is an artificially manufactured molecule, a small protein chain that structurally mimics the action of the body’s naturally occurring hormone, Somatostatin. The chemical alteration provides Octreotide with increased stability and a significantly longer half-life compared to the natural hormone, making it suitable for systemic therapeutic use. Azestan is often available in a specific immediate-release solution designed for precise, rapid control of acute secretory episodes.

Classification and General Purpose

Azestan belongs to the pharmacological class of Somatostatin Analogs. This class of agent works by binding to specific receptors throughout the body, acting as a potent inhibitor of hormone release. This mechanism allows the drug to regulate and suppress the excessive secretion of various powerful chemical messengers, including Growth Hormone, Glucagon, and several gastrointestinal peptides. Its efficacy in this role is clinically recognized for stabilizing biological systems experiencing uncontrolled hormonal activity, such as controlling severe, refractory diarrhea associated with certain tumors.

Formulations and Delivery Profile

The product is offered in two principal functional formulations distinguished by their release profile: an immediate-release solution and a long-acting suspension (LAR Depot). The immediate-release form is intended for quick stabilization. Conversely, the long-acting suspension employs specialized carrier technology to ensure the Octreotide is released gradually over several weeks. This distinction in delivery allows for the selection of a formulation tailored either for short-term symptomatic stability or for consistent, long-term hormonal suppression via reduced dosing frequency, providing a therapeutic advantage over therapies that require constant daily administration.

Regulatory References

NIH MedlinePlus: Octreotide

What side effects are possible with Azestan?

Possible Side Effects and Safety Information

Azestan, which contains the antihistamine azelastine hydrochloride nasal spray, is generally well-tolerated, but like all medications, it can cause side effects. These are typically mild and often resolve with continued use.

Common Side Effects

The most frequently reported side effects associated with Azestan include:

Bitter taste in the mouth (dysgeusia)
Headache
Somnolence or drowsiness
Nasal discomfort, such as burning or stinging
Epistaxis (nosebleeds)
Fatigue or tiredness
Pharyngitis (sore throat)

Important Safety Warnings

Somnolence and CNS Depressants

Azelastine nasal spray may cause drowsiness or impaired mental alertness. Patients should exercise caution when operating heavy machinery, driving a vehicle, or performing other tasks requiring complete mental focus until they know how the medication affects them. The concurrent use of Azestan with alcohol or other Central Nervous System (CNS) depressants may intensify these effects and should be avoided.

Hypersensitivity

Azestan is contraindicated in patients with a known hypersensitivity or allergic reaction to azelastine hydrochloride or any other ingredients in the formulation. If signs of a serious allergic reaction occur—such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat—immediate medical attention is required.

Consult a healthcare professional about all existing medical conditions and all other medications being taken, including over-the-counter drugs and herbal supplements, to avoid potential drug interactions.

Overdose and Emergency Response

Suspected overdose requires that immediate medical attention be sought due to the potential for severe, life-threatening outcomes officially documented in regulatory information. Documented manifestations include signs of cardiovascular instability, such as hypotension, bradycardia, and arrhythmia, alongside systemic effects like lethargy, weakness, diarrhea, and flushing. Metabolic disturbances include both hypoglycemia and hyperglycemia.

Overdose is explicitly associated with severe, potentially fatal consequences, including cardiac arrest, brain hypoxia, and lactic acidosis. The official labeling highlights a specific risk for developing higher degree atrioventricular blocks, particularly when high doses of Azestan are administered via continuous intravenous infusion. Contact emergency services immediately upon recognizing these or any other severe, life-threatening symptoms.

Management is focused on providing symptomatic and supportive treatment. As a required procedural step, appropriate cardiac monitoring is necessary, especially following high-dose exposure. No specific antidote for Octreotide overdose is currently documented in the official labeling. Additionally, patients with existing renal impairment or liver cirrhosis may experience a prolonged half-life, which can extend the duration of overdose effects and require extended observation.

Therapeutic Uses of Azestan

What Azestan treats: main uses and benefits

Azestan is a medication primarily indicated for the management of symptoms associated with allergic conditions. It belongs to a class of drugs known as antihistamines, which work by blocking the effects of histamine, a natural substance in the body that triggers allergic reactions.

Principal Applications

The medication is most commonly used to address the following conditions:

Allergic Rhinitis: This includes both seasonal allergies and perennial allergies. It helps alleviate symptoms such as sneezing, itching, and a congested or runny nose.
Allergic Conjunctivitis: Azestan is used to treat ocular symptoms of allergies, including redness, itching, and watering of the eyes.
Urticaria: It is indicated for the relief of symptoms associated with chronic hives, such as localized swelling and itchy skin rashes.

Benefits and Mechanisms

By inhibiting the H1 histamine receptors, the medication prevents the inflammatory cascade that follows exposure to allergens like pollen, dust mites, or pet dander. The primary benefits observed during treatment include:

Reduction in Nasal Discomfort: By decreasing the inflammatory response in the nasal passages, it facilitates easier breathing and reduces persistent sneezing.
Ocular Relief: It targets the irritation in the mucous membranes of the eyes, providing a reduction in redness and tearing.
Sustained Action: The pharmacological profile of the medication typically allows for a consistent effect over a defined period, assisting in the management of chronic allergic triggers.
Improved Quality of Life: By managing these physical symptoms, the medication helps reduce the impact that allergic reactions can have on daily activities and sleep quality.

Regulatory References

NIH MedlinePlus overview on Azelastine Nasal Spray

Eligibility and Restrictions for Use

Who Can and Cannot Use Azestan?

Azestan (Octreotide) is intended for use in adult patients and is subject to strict regulatory constraints based on patient history, age, and physiological status.

Absolute Contraindications

The medicine is contraindicated for any individual with a documented hypersensitivity to Octreotide or any other component of the formulation. Use is also prohibited in patients who have experienced a severe anaphylactoid reaction to the drug.

Restrictions Based on Age and Organ Function

Pediatric Use: Safety and efficacy have not been established in the general pediatric population. Special consideration is given to children under two years old, where severe events have been reported.
Geriatric Use: Dose adjustment may be required for older adults due to age-related changes in drug clearance.
Organ Impairment: Patients with severe hepatic impairment (cirrhosis) or renal impairment requiring dialysis are eligible only under restricted use, often necessitating a dose adjustment by a healthcare provider.

Reproductive Status and Comorbidities

Use is not recommended during pregnancy or while breastfeeding (lactation). Females of child-bearing potential must be advised to use adequate contraception due to the potential for the medicine to restore fertility. Caution is advised for patients with a history of cholelithiasis (gallstones) or pre-existing cardiovascular disease.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interaction patterns for Azestan (Azelastine) nasal spray as documented in official government regulatory information.

Pharmacodynamic and Substance Interactions

Co-administration with other Central Nervous System (CNS) Depressants, such as sedatives or tranquilizers, is associated with the risk of additive CNS depressant effects. These effects may result in reduced alertness and potential impairment of CNS performance. Consequently, use with alcohol should be avoided, as it may cause additional impairment of performance.

Pharmacokinetic Interactions

Pharmacokinetic interaction studies have documented that co-administration of oral Cimetidine, a known cytochrome P450 inhibitor, caused an increase in the systemic exposure of Azelastine. Specifically, the mean peak plasma concentration ( C max) and the area under the curve ( AUC) of Azelastine were increased by approximately 65%. This outcome establishes a potential pharmacokinetic constraint when Azestan is co-administered with certain metabolic inhibitors. Conversely, studies with oral Ketoconazole and Erythromycin, other enzyme-inhibiting agents, did not demonstrate significant effects on the pharmacokinetics of Azelastine.

Mechanism of Action

Azestan, chemically known as azelastine, functions as an inverse agonist and antagonist with a primary molecular target of the Histamine H1-receptor. The molecule binds selectively to this G-protein coupled receptor, blocking the effect of endogenous histamine. This H1-receptor antagonism primarily modulates signaling in peripheral tissues, including the nasal mucosa.

Beyond H1-receptor antagonism, Azestan also exhibits effects on inflammatory cell processes. It interacts with mast cells to induce stabilization, which inhibits the Ca^2+-dependent release of preformed inflammatory mediators, including histamine. Furthermore, it modulates the arachidonic acid cascade by inhibiting the generation and release of leukotrienes from inflammatory cells, likely via the inhibition of 5-lipoxygenase (5-LO) translocation rather than direct enzymatic inhibition. The overall result is a system-level modulation of the signaling cascade responsible for microcirculatory changes and increased vascular permeability.

Dosage and Administration Information

How to Use Azestan: Administration Guidelines

Azestan, which contains the active ingredient azelastine, is used according to specific protocols to ensure accurate intranasal delivery. The medication is available as a nasal spray solution in 0.1% and 0.15% strengths and is administered exclusively via the intranasal route.

Standard Dosing and Frequency

Regimens are determined by patient age and the specific use case. For adults 12 years and older, the typical dosing involves 1 or 2 sprays per nostril, administered twice daily (bid), or 2 sprays per nostril once daily (qd) when using the 0.15% strength for Seasonal Allergic Rhinitis. The twice-daily regimen is generally separated by a 12-hour interval.

Age-Specific Administration

Specific reduced regimens are established for pediatric populations. Children aged 6 to 11 years are instructed to use 1 spray per nostril twice daily. This same regimen of 1 spray per nostril twice daily is also used for the population group aged 2 to 5 years, using the 0.1% concentration.

Preparation and Device Protocol

Proper use requires specific device handling. The nasal spray pump must be primed with 4 to 6 sprays until a fine mist appears before its initial use. If the device remains unused for 3 or more days, it must be reprimed with 2 sprays to restore dose accuracy. Furthermore, the container must be discarded after the designated total number of metered sprays has been used, regardless of any remaining liquid, to ensure consistent dose delivery.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azestan (Octreotide)

This overview summarizes the formal research studies used in the clinical evaluation of Azestan (Octreotide). It focuses on the types of trials that were conducted, the outcomes researchers measured, and the specific populations that were included.

Evidence for Use in Acromegaly (Excess Growth Hormone Management)

The evidence base relies on Randomized Controlled Trials (RCTs) and long-term observational studies conducted in adults, including those commencing systemic treatment or those who had inadequate responses to prior surgery. The main focus of these studies was on biochemical metrics, specifically monitoring the concentration of Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1). Researchers also monitored tumor volume over time in the study populations. A substantial volume of data exists for biochemical monitoring; however, some studies focusing on tumor size monitoring were open-label, lacking a direct control group.

Evidence for Use in Carcinoid Syndrome (Symptom Control)

Research includes Phase III RCTs and systematic reviews that primarily explored how symptoms change over time in adult populations with metastatic neuroendocrine tumors. Key outcomes monitored were those related to the frequency and severity of episodic manifestations: diarrhea and flushing episodes. Regulatory documents clarify that the relationship of Octreotide to tumor size, rate of growth, or development of metastases is not fully established for this indication; research is mainly framed around examining the functional, hormone-related symptoms.

Areas of Uncertainty and Remaining Research Gaps

For many indications, the research provides context but does not determine whether an individual will respond similarly over very long timeframes, and long-term effects are not fully established across all contexts. Furthermore, research for rare tumor-related conditions like VIPoma relies on smaller clinical trials, which limits insight into the durability of symptomatic monitoring due to modest sample sizes. In acute settings, such as Malignant Bowel Obstruction (MBO), findings were mixed, contributing to uncertainty regarding the certainty of acute symptomatic monitoring.

Key Studies & References Octreotide - StatPearls - NCBI Bookshelf (Review of indications, clinical studies, and monitoring)

Frequently Asked Questions (FAQ)

Common questions about Azestan (FAQ)

Q: How quickly does Azestan typically start working after it is taken?

A: Official product information indicates that the nasal spray formulation (azelastine) is fast-acting, with the onset of relief reported in clinical studies as soon as 5 minutes. The immediate-release injectable formulation (octreotide) is characterized by rapid systemic absorption, reaching peak concentration within 30 minutes following subcutaneous administration.

Q: Does Azestan build up in the body over time?

A: Official pharmacokinetic data indicates that the immediate-release injectable formulation (octreotide) does not show significant accumulation with repeated subcutaneous use. However, the long-acting injectable suspension is designed for controlled release, and steady-state concentrations are typically reached after approximately three months of regular dosing.

Q: What is the duration of Azestan's intended effect?

A: The nasal spray formulation (azelastine) is described as having a duration of effect of approximately 12 hours, which is consistent with its authorized use frequency. The long-acting injectable formulation (octreotide LAR) is designed to maintain consistent therapeutic levels for a prolonged period, typically between three to four weeks.

Q: Can Azestan cause changes in appetite or body weight?

A: Official reports indicate that the nasal spray formulation (azelastine) lists weight gain as a less common side effect. For the injectable formulation (octreotide), weight loss has been observed in some patients, sometimes associated with a known side effect called pancreatic exocrine insufficiency (PEI).

Q: Is it officially described if Azestan interacts with commonly used pain relievers?

A: Official regulatory documents do not specifically detail interaction studies with common over-the-counter pain relievers. However, the nasal spray formulation (azelastine) carries warnings about potential additive effects when used alongside other Central Nervous System (CNS) depressants.

Q: Does taking Azestan with food affect how it works?

A: Official product information states that food has no influence on the absorption of the nasal spray formulation (azelastine). For the injectable formulation (octreotide), timing the injections between meals is sometimes suggested to help manage potential gastrointestinal side effects.

Q: Are there any official reports of Azestan causing sleep disturbances?

A: The injectable formulation (octreotide) lists insomnia as a side effect reported in clinical trials. The nasal spray formulation (azelastine) commonly causes somnolence or drowsiness, which is an impairment of mental alertness that may affect sleep patterns.

Q: What should be done if a scheduled dose of Azestan is missed?

A: Regulatory information regarding short-acting formulations describes the process of taking a missed dose as soon as possible, or skipping the missed dose if it is almost time for the next scheduled dose. For the long-acting injectable formulation (octreotide LAR), official guidance indicates that patients should consult their healthcare provider.

Q: Is Azestan available as a generic drug?

A: Studies and official documents indicate that the active ingredients in Azestan, azelastine and octreotide, are available in generic formulations. These generic versions are authorized by regulatory bodies for use in various regions.

Q: Is Azestan approved for use in children?

A: The approval for pediatric use differs depending on the formulation. The nasal spray (azelastine) has specific dosing regimens approved for children as young as 2 years old. In contrast, the injectable formulation (octreotide) has not had its safety and efficacy established for the general pediatric population.

Q: Why do some people need to take Azestan for a long period?

A: The injectable formulation (octreotide) is classified as a Somatostatin Analog, used to manage chronic conditions characterized by uncontrolled hormonal activity. Consistent, long-term suppression is often consistent with the management of chronic conditions, which typically involves extended therapeutic suppression.

Q: Can Azestan interfere with common blood tests or medical screenings?

A: Official safety information indicates that the injectable formulation (octreotide) is known to affect glucose regulation and may cause a decrease in Vitamin B12 levels. These effects can influence the results of related blood tests and medical screenings.

Q: What percentage of users experience the most common side effect of Azestan?

A: Regulatory documents classify the frequency of side effects. For the nasal spray formulation (azelastine), the most common side effect, a bitter taste (dysgeusia), is described as common, meaning it occurs in approximately 1% to 10% of users.

Q: Is Azestan approved in countries outside of the United States?

A: Official international reports confirm that the active ingredients (azelastine and octreotide) are approved and regulated for use in numerous countries. This includes regions across Europe, North America, and Australia, among others.

Q: Can Azestan be taken alongside standard over-the-counter cold medicines?

A: Regulatory documents contain warnings regarding the use of the nasal spray formulation (azelastine) when taking it alongside other Central Nervous System (CNS) depressants. This is relevant because many over-the-counter cold medicines contain ingredients classified as CNS depressants.

Q: Is a dry mouth an expected side effect of Azestan?

A: According to official listings, dryness of the mouth is listed as a less common side effect associated with the nasal spray formulation (azelastine).

Q: What is the maximum duration for which Azestan use has been studied?

A: Regulatory guidance authorizes the continued use of the injectable formulation (octreotide) for chronic conditions like neuroendocrine tumors and acromegaly. Authorization periods for long-term management often extend for 12 months or longer, provided clinical benefit is maintained.

Q: Is Azestan used for short-term relief or long-term management?

A: The nasal spray formulation (azelastine) is generally intended for seasonal or chronic symptom relief. The injectable formulation (octreotide) is available in forms suited both for quick stabilization (short-term) and for long-term chronic hormonal suppression.

Q: Are there any known long-term effects associated with using Azestan?

A: Official research for the injectable formulation (octreotide) notes that the long-term effects are not fully established across all contexts of use. Regulatory bodies maintain continuous post-marketing surveillance to monitor safety over extended timeframes for both formulations.

Q: What is the primary difference between Azestan and other similar medicines?

A: Azestan (octreotide) is distinguished from other somatostatin analogs by its specific affinity profile for somatostatin receptors. Azestan (azelastine) is differentiated by its dual mechanism of action, which includes H1-receptor antagonism and the inhibition of inflammatory mediator release.

Q: Why is Azestan sometimes referred to as a preventative drug?

A: The nasal spray formulation (azelastine) is sometimes referred to as preventative due to its anti-inflammatory action, which inhibits the release of preformed inflammatory mediators. The long-acting injectable formulation (octreotide) is preventative by aiming for sustained suppression of hormone secretion in chronic conditions, preventing acute episodes.

Q: What conditions, other than the main indication, have been examined in research for Azestan?

A: Regulatory research has examined the injectable formulation (octreotide) in other conditions beyond its main indications. These conditions include VIPoma and Malignant Bowel Obstruction (MBO).

Q: Does Azestan require special storage conditions, beyond keeping it cool and dry?

A: Yes, official instructions include that the product must be protected from freezing. Furthermore, certain formulations of the injectable solution (octreotide) may require initial storage in the refrigerator before being brought to room temperature for use.

How should Azestan be stored and disposed of?

How to Store and Dispose of Azestan

The official regulatory guidelines specify precise conditions for storing and discarding Azestan (Azelastine) to maintain product stability and safety.

Storage Requirements

Temperature: Store at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The product must be protected from freezing.
Container and Protection: Keep the medicine in its original container, tightly closed, and store it away from excess heat and moisture. Child-safety rules mandate keeping the product out of the reach of children.

Stability and Disposal

Shelf-Life: Single-dose containers must be discarded immediately after use. Multi-dose containers must be discarded after a limited in-use period (e.g., 28 days for some opened formulations).
Disposal: Do not dispose of unused or expired Azestan by flushing it down the toilet or pouring it into a drain. Disposal should follow local regulatory instructions, typically by utilizing an authorized drug take-back program.

Azestan